Mina Khosravifar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mina Khosravifar has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ali Bitaraf
School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
1 shared publication - Amir Ali Mahboobipour
Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Amir Shahidolahi
School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
1 shared publication - Homa Babaei
Department of Pediatrics, Imam Reza Hospital, Kermanshah University of Medical Science, Kermanshah, Iran
1 shared publication - Pourang Mohammadi
School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
1 shared publication
Latest Publications
- Open Access
- 13 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (37) , e39647
Effects of synbiotics on necrotizing enterocolitis and full enteral feeding in very low birth weight infants: A double-blind, randomized controlled trial
Background: Necrotizing enterocolitis (NEC) is a multifactorial disease primarily affecting infants with very low birth weight (VLBW). Research has shown that the pathogenesis of NEC is associated with abnormal bacterial colonization. Synbiotics, dietary supplements containing probiotics (beneficial bacteria) and prebiotics (non-digestible food), can alter the gut microbiome. Methods: A double-blind, randomized controlled trial was conducted to assess the efficacy of PediLact ® , an oral drop multi-strain synbiotic containing Lactobacillus rhamnosus , Lactobacillus reuteri , and Bifidobacterium infantis , on nutritional parameters and the occurrence of NEC in VLBW neonates. In this study, 118 VLBW neonates from neonatal intensive care units were randomly allocated in a 1:1 ratio to receive either a synbiotic or a placebo. The synbiotic administration continued until the infant was fully fed. The primary outcomes were the occurrence of NEC and the number of days required to achieve full enteral feeding. Log-binomial regression and ANOVA/ANCOVA models were used for analysis. Results: In the group that received the synbiotic, the incidence of NEC decreased significantly (adjusted RR = 0.22, 95% CI: 0.07–0.72, P value = .01; adjusted RD = −0.22, 95% CI: −0.33 to −0.12, P value < .001; NNT = 5). Additionally, feeding intolerance was less frequent in this group (adjusted RR = 0.27, 95% CI: 0.14–0.51, P value < .001; NNT = 3). Furthermore, consumption of the synbiotic was associated with significant weight gain (approximately 40 g) in infants (adjusted SMD = 0.63; 95% CI: 0.26–1.00, P value < .001). The duration of hospitalization and the time required to reach full enteral feeding were also significantly shorter in the synbiotic group (by approximately 3 days). No serious side effects were reported. Conclusion: Prescribing multi-strain synbiotics reduces the incidence of NEC in VLBW infants and has beneficial effects on breastfeeding tolerance and weight gain velocity. Therefore, physicians may consider prescribing synbiotics to VLBW neonates.
- 13 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (37) , e39647
Open AccessEffects of synbiotics on necrotizing enterocolitis and full enteral feeding in very low birth weight infants: A double-blind, randomized controlled trial
Background: Necrotizing enterocolitis (NEC) is a multifactorial disease primarily affecting infants with very low birth weight (VLBW). Research has shown that the pathogenesis of NEC is associated with abnormal bacterial colonization. Synbiotics, dietary supplements containing probiotics (beneficial bacteria) and prebiotics (non-digestible food), can alter the gut microbiome. Methods: A double-blind, randomized controlled trial was conducted to assess the efficacy of PediLact ® , an oral drop multi-strain synbiotic containing Lactobacillus rhamnosus , Lactobacillus reuteri , and Bifidobacterium infantis , on nutritional parameters and the occurrence of NEC in VLBW neonates. In this study, 118 VLBW neonates from neonatal intensive care units were randomly allocated in a 1:1 ratio to receive either a synbiotic or a placebo. The synbiotic administration continued until the infant was fully fed. The primary outcomes were the occurrence of NEC and the number of days required to achieve full enteral feeding. Log-binomial regression and ANOVA/ANCOVA models were used for analysis. Results: In the group that received the synbiotic, the incidence of NEC decreased significantly (adjusted RR = 0.22, 95% CI: 0.07–0.72, P value = .01; adjusted RD = −0.22, 95% CI: −0.33 to −0.12, P value < .001; NNT = 5). Additionally, feeding intolerance was less frequent in this group (adjusted RR = 0.27, 95% CI: 0.14–0.51, P value < .001; NNT = 3). Furthermore, consumption of the synbiotic was associated with significant weight gain (approximately 40 g) in infants (adjusted SMD = 0.63; 95% CI: 0.26–1.00, P value < .001). The duration of hospitalization and the time required to reach full enteral feeding were also significantly shorter in the synbiotic group (by approximately 3 days). No serious side effects were reported. Conclusion: Prescribing multi-strain synbiotics reduces the incidence of NEC in VLBW infants and has beneficial effects on breastfeeding tolerance and weight gain velocity. Therefore, physicians may consider prescribing synbiotics to VLBW neonates.